Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Talha Badar

Showing results (91-100 of 113) with videos related to

Pageof 12
Sort By:
Blood|April 18, 2024
Real-world and clinical trial outcomes in large B-cell lymphoma with axicabtagene ciloleucel across race and ethnicityFrederick L Locke, Tanya Siddiqi, Caron A Jacobson, et al.
Blood Advances|January 7, 2026
Spectrum, prevalence, and clinical correlates of PPM1D mutations in patients with clonal hematopoiesis and clonal cytopeniasTalha Badar, Ludovica Marando, Eric Latorre-Crespo, et al.
European Journal of Haematology|May 11, 2021
Intensive induction regimens after deferring initial therapy for mantle cell lymphoma are not associated with improved survivalKrithika Shanmugasundaram, Subir Goyal, Jeffery Switchenko, et al.
Blood Cancer Journal|August 14, 2025
Clinical and molecular characterization of TP53-mutant acute lymphoblastic leukemia in adultsEthan J Harris, Diren Arda Karaoglu, Madina Sukhanova, et al.
Blood Advances|September 13, 2021
Early relapse identifies MCL patients with inferior survival after intensive or less intensive frontline therapyDavid A Bond, Jeffrey M Switchenko, Diego Villa, et al.
Cancer|September 23, 2020
African Americans with translocation t(11;14) have superior survival after autologous hematopoietic cell transplantation for multiple myeloma in comparison with Whites in the United StatesTalha Badar, Parameswaran Hari, Omar Dávila, et al.
American Journal of Hematology|December 13, 2024
Mayo Genetic Risk Models for Newly Diagnosed Acute Myeloid Leukemia Treated With Venetoclax + Hypomethylating AgentNaseema Gangat, Azeem Elbeih, Nour Ghosoun, et al.
Blood Advances|March 14, 2025
Evidence-based risk stratification of myeloid neoplasms harboring TP53 mutationsMithun Vinod Shah, Kevin Hung, Anmol Baranwal, et al.
Blood|June 2, 2026
Ziftomenib with venetoclax and azacitidine in relapsed/refractory NPM1-mutated acute myeloid leukemiaEunice S Wang, Harry P Erba, Amer M Zeidan, et al.
Blood Cancer Journal|May 7, 2025
Validation of the 5th edition of the World Health Organization and International Consensus Classification guidelines for TP53-mutated myeloid neoplasm in an independent international cohortMithun Vinod Shah, Kevin Hung, Anmol Baranwal, et al.
Pageof 12

Showing results (91-100 of 113) with videos related to

Sort By:
Pageof 12
Blood|April 18, 2024
Real-world and clinical trial outcomes in large B-cell lymphoma with axicabtagene ciloleucel across race and ethnicityFrederick L Locke, Tanya Siddiqi, Caron A Jacobson, et al.
Blood Advances|January 7, 2026
Spectrum, prevalence, and clinical correlates of PPM1D mutations in patients with clonal hematopoiesis and clonal cytopeniasTalha Badar, Ludovica Marando, Eric Latorre-Crespo, et al.
European Journal of Haematology|May 11, 2021
Intensive induction regimens after deferring initial therapy for mantle cell lymphoma are not associated with improved survivalKrithika Shanmugasundaram, Subir Goyal, Jeffery Switchenko, et al.
Blood Cancer Journal|August 14, 2025
Clinical and molecular characterization of TP53-mutant acute lymphoblastic leukemia in adultsEthan J Harris, Diren Arda Karaoglu, Madina Sukhanova, et al.
Blood Advances|September 13, 2021
Early relapse identifies MCL patients with inferior survival after intensive or less intensive frontline therapyDavid A Bond, Jeffrey M Switchenko, Diego Villa, et al.
Cancer|September 23, 2020
African Americans with translocation t(11;14) have superior survival after autologous hematopoietic cell transplantation for multiple myeloma in comparison with Whites in the United StatesTalha Badar, Parameswaran Hari, Omar Dávila, et al.
American Journal of Hematology|December 13, 2024
Mayo Genetic Risk Models for Newly Diagnosed Acute Myeloid Leukemia Treated With Venetoclax + Hypomethylating AgentNaseema Gangat, Azeem Elbeih, Nour Ghosoun, et al.
Blood Advances|March 14, 2025
Evidence-based risk stratification of myeloid neoplasms harboring TP53 mutationsMithun Vinod Shah, Kevin Hung, Anmol Baranwal, et al.
Blood|June 2, 2026
Ziftomenib with venetoclax and azacitidine in relapsed/refractory NPM1-mutated acute myeloid leukemiaEunice S Wang, Harry P Erba, Amer M Zeidan, et al.
Blood Cancer Journal|May 7, 2025
Validation of the 5th edition of the World Health Organization and International Consensus Classification guidelines for TP53-mutated myeloid neoplasm in an independent international cohortMithun Vinod Shah, Kevin Hung, Anmol Baranwal, et al.
Pageof 12